[
  {
    "date": "2023-12-30",
    "symbol": "LIXTW",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2023,
    "currentfiscalyearenddate": "--12-31",
    "entityfilenumber": "001-39717",
    "entityregistrantname": "LIXTE BIOTECHNOLOGY HOLDINGS, INC.",
    "entitycentralindexkey": 1335105,
    "entitytaxidentificationnumber": "20-2903526",
    "entityincorporationstatecountrycode": "DE",
    "entityaddressaddressline1": "680     East Colorado Boulevard",
    "entityaddressaddressline2": "Suite 180",
    "entityaddresscityortown": "Pasadena",
    "entityaddressstateorprovince": "CA",
    "entityaddresspostalzipcode": 91101,
    "cityareacode": "(631)",
    "localphonenumber": "830-7092",
    "security12btitle": "Common     Stock, par value $0.0001 per share",
    "tradingsymbol": "LIXT",
    "securityexchangename": "NASDAQ",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "icfrauditorattestationflag": "false",
    "documentfinstmterrorcorrectionflag": "false",
    "auditorfirmid": 572,
    "auditorname": "Weinberg & Company, P.A",
    "auditorlocation": "Los Angeles, California",
    "cashandcashequivalentsatcarryingvalue": 4203488,
    "advancesonresearchanddevelopmentcontractservices": 78016,
    "prepaidinsurance": 17116,
    "otherprepaidexpensecurrent": 10000,
    "assetscurrent": 4308620,
    "assets": 4308620,
    "accountspayableandaccruedliabilitiescurrent": 36250,
    "researchanddevelopmentcontractliabilitiescurrent": 157100,
    "liabilitiescurrent": 313858,
    "preferredstockvalue": 3500000,
    "commonstockvalue": 225,
    "additionalpaidincapital": 48976265,
    "retainedearningsaccumulateddeficit": -48481728,
    "stockholdersequity": 3994762,
    "liabilitiesandstockholdersequity": 4308620,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 10000000,
    "preferredstocksharesissued": 350000,
    "preferredstocksharesoutstanding": 350000,
    "preferredstockliquidationpreference": 10,
    "convertiblepreferredstocksharesissueduponconversion": 72917,
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": 100000000,
    "commonstocksharesissued": 2249290,
    "commonstocksharesoutstanding": 2249290,
    "generalandadministrativeexpense": 1718180,
    "legalfees": 978244,
    "othercostandexpenseoperating": 1495712,
    "researchanddevelopmentexpense": 898100,
    "operatingexpenses": 5090236,
    "operatingincomeloss": -5090236,
    "investmentincomenonoperating": 17486,
    "interestexpense": 16233,
    "foreigncurrencytransactiongainlossbeforetax": 1954,
    "netincomeloss": -5087029,
    "earningspersharebasic": -2.66,
    "earningspersharediluted": -2.66,
    "weightedaveragenumberofsharesoutstandingbasic": 1915838,
    "weightedaveragenumberofdilutedsharesoutstanding": 1915838,
    "allocatedsharebasedcompensationexpense": 773203,
    "sharesoutstanding": 350000,
    "stockissuedduringperiodvaluenewissues": 18,
    "stockissuedduringperiodsharesnewissues": 180000,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 773203,
    "stockissuedduringperiodvalueother": 41,
    "stockissuedduringperiodsharesother": 403334,
    "stockissuedduringperiodvaluestockoptionsexercised": 6281,
    "stockissuedduringperiodsharesstockoptionsexercised": 1250,
    "sharebasedcompensationincludedingeneralandadministrativecost": 773203,
    "increasedecreaseinadvancesonresearchanddevelopmentcontractservices": -69001,
    "increasedecreaseinprepaidinsurance": -32108,
    "increasedecreaseinprepaidexpensesother": -1350,
    "increasedecreaseinaccountspayableandaccruedliabilities": -73976,
    "increasedecreaseinresearchanddevelopmentcontractliabilities": -7922,
    "netcashprovidedbyusedinoperatingactivities": -4293265,
    "proceedsfromissuanceofcommonstock": 3137039,
    "proceedsfromwarrantexercises": 41,
    "proceedsfromstockoptionsexercised": 6281,
    "netcashprovidedbyusedinfinancingactivities": 3143361,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -1149904,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 4203488,
    "interestpaidnet": 16233,
    "contractualobligation": 6344000,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 72917,
    "numberofoperatingsegments": 1,
    "numberofreportablesegments": 1,
    "cashfdicinsuredamount": 250000,
    "cashsipcinsuredamount": 500000,
    "concentrationriskpercentage1": 0.233,
    "foreigncurrencyexchangeratetranslation1": 1.0824,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsoutstandingnumber": 808365,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionoutstandingweightedaverageexerciseprice": 16.407,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsgranted": 618334,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptiongrantsinperiodweightedaverageexerciseprice": 6.034,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionsoutstandingweightedaverageremainingcontractualterm": "P3Y11M26D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsexercisablenumber": 808365,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionweightedaverageexercisepriceexercisable": 16.407,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionsexercisableweightedaverageremainingcontractualterm": "P3Y11M26D",
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 6,
    "preferredstockconversionbasis": "Eachshare of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 0.20833 shares of common stock (subjectto customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversionrate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000",
    "conversionofstocksharesconverted1": 0.20833,
    "proceedsfromissuanceofconvertiblepreferredstock": 21875000,
    "shareprice": 57,
    "classofwarrantorrightoutstanding": 1497000,
    "officerscompensation": 190860,
    "salariesandwages": 163479,
    "paymentsforrent": 15571,
    "managementfeepayable": 100000,
    "employeebenefitsandsharebasedcompensation": 62500,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 25000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardexpirationperiod": "P5Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingrights": "vesting 50% on the grant date and the remaining 50% vesting 12.5% on the last day ofeach calendar quarter beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continuedservice",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.04843,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.3805,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P4Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 495000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 15.33,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiod": 290000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 2.492,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 5.025,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexpirationsinperiod": 126146,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexpirationsinperiodweightedaverageexerciseprice": 28.687,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P3Y10M2D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 252292,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 28.387,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P2Y10M20D",
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeupperrangelimit": 1.95,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofoutstandingoptions": 250000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptions": 20833,
    "commonstockcapitalsharesreservedforfutureissuance": 255000,
    "sharebasedcompensation": 61501,
    "deferredcompensationarrangementwithindividualcompensationexpense": 670000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestexercisableweightedaverageremainingcontractualterm1": "P26M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 2.35,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 8000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestednumberofshares": 299791,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 612000,
    "deferredtaxassetsinprocessresearchanddevelopment": 844000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1631000,
    "deferredtaxassetsoperatinglosscarryforwards": 8601000,
    "deferredtaxassetsgross": 11688000,
    "deferredtaxassetsvaluationallowance": 11688000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": 0.06,
    "effectiveincometaxratereconciliationsharebasedcompensationexcesstaxbenefitpercent": -0.104,
    "effectiveincometaxratereconciliationadjustmenttodeferredtaxasset": 0.008,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": -0.174,
    "deferredtaxassetsoperatinglosscarryforwardsdomestic": 28111000,
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 32617000,
    "operatinglosscarryforwardslimitationsonuse": "The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. UnutilizedPNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurredin post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040.",
    "clinicaltrialdescription": "LB-100    combined with carboplatin, etoposide and atezolizumab in small cell lung cancer",
    "contractualclinicaltrialperiodstartdate": "March    2021",
    "contractualclinicaltrialperiodenddate": "March    2026",
    "numberofpatientintrial": 14,
    "othercommitment": 2433000,
    "deferredcosts": 447512,
    "estimatedadditionalcommitment": 800000,
    "inventorypartsandcomponentsnetofreserves": 1144000,
    "amountrelatedtomilestonepayment": 684652,
    "operatingcostsandexpenses": 9109,
    "consultingandadvisorycashfee": 16000,
    "reimbursementexpense": 120000
  },
  {
    "date": "2022-12-30",
    "symbol": "LIXTW",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentperiodenddate": "2022-12-31",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2022,
    "currentfiscalyearenddate": "--12-31",
    "entityfilenumber": "001-39717",
    "entityregistrantname": "LIXTE BIOTECHNOLOGY HOLDINGS, INC.",
    "entitycentralindexkey": 1335105,
    "entitytaxidentificationnumber": "20-2903526",
    "entityincorporationstatecountrycode": "DE",
    "entityaddressaddressline1": "680     East Colorado Boulevard",
    "entityaddressaddressline2": "Suite 180",
    "entityaddresscityortown": "Pasadena",
    "entityaddressstateorprovince": "CA",
    "entityaddresspostalzipcode": 91101,
    "cityareacode": "(631)",
    "localphonenumber": "830-7092",
    "security12btitle": "Common     Stock, par value $0.0001 per share",
    "tradingsymbol": "LIXT",
    "securityexchangename": "NASDAQ",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "icfrauditorattestationflag": "false",
    "auditorfirmid": 572,
    "auditorname": "Weinberg & Company, P.A",
    "auditorlocation": "Los Angeles, California",
    "cashandcashequivalentsatcarryingvalue": 5353392,
    "advancesonresearchanddevelopmentcontractservices": 147017,
    "prepaidinsurance": 49224,
    "prepaidexpenseandotherassetscurrent": 10380,
    "assetscurrent": 5560013,
    "assets": 5560013,
    "accountspayableandaccruedliabilitiescurrent": 229764,
    "researchanddevelopmentcontractliabilitiescurrent": 165022,
    "liabilitiescurrent": 394786,
    "preferredstockvalue": 3500000,
    "commonstockvalue": 1664,
    "additionalpaidincapital": 45058262,
    "retainedearningsaccumulateddeficit": -43394699,
    "stockholdersequity": 5165227,
    "liabilitiesandstockholdersequity": 5560013,
    "accountspayablerelatedpartiescurrent": 46982,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 10000000,
    "preferredstocksharesissued": 350000,
    "preferredstocksharesoutstanding": 350000,
    "convertiblepreferredstocksharesissueduponconversion": 729167,
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": 100000000,
    "commonstocksharesissued": 16646593,
    "commonstocksharesoutstanding": 16646593,
    "generalandadministrativeexpense": 2547615,
    "legalfees": 1268308,
    "othercostandexpenseoperating": 1146289,
    "researchanddevelopmentexpense": 1349269,
    "operatingexpenses": 6311481,
    "operatingincomeloss": -6311481,
    "investmentincomenonoperating": 11195,
    "interestexpense": 8875,
    "foreigncurrencytransactiongainlossbeforetax": -3374,
    "netincomeloss": -6312535,
    "earningspersharebasic": -0.4,
    "weightedaveragenumberofsharesoutstandingbasic": 15820292,
    "allocatedsharebasedcompensationexpense": 1502776,
    "sharesoutstanding": 350000,
    "stockissuedduringperiodvaluenewissues": 290,
    "stockissuedduringperiodsharesnewissues": 2900000,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 1546040,
    "generalandadministrativestockbasedcompensationexpenses": 1502776,
    "researchanddevelopmentcosts": 43264,
    "increasedecreaseinadvancesonresearchanddevelopmentcontractservices": -3224,
    "increasedecreaseinprepaidinsurance": -59805,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 131,
    "increasedecreaseinaccountspayableandaccruedliabilities": 3799,
    "increasedecreaseinresearchanddevelopmentcontractliabilities": 88061,
    "netcashprovidedbyusedinoperatingactivities": -4611737,
    "proceedsfromissuanceofcommonstock": 5141384,
    "netcashprovidedbyusedinfinancingactivities": 5141384,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 529647,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 5353392,
    "interestpaidnet": 8875,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 729167,
    "cashfdicinsuredamount": 250000,
    "cashsipcinsuredamount": 500000,
    "concentrationriskpercentage1": 0.1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsoutstandingnumber": 1900310,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionoutstandingweightedaveragenumberofshare": 5.016,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsgranted": 290000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptiongrantsinperiodweightedaverageexerciseprice": 2,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsforfeituresandexpirations": 1500000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionforfeitedorexpiredinperiodweightedaverageexerciseprice": 6,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionsoutstandingweightedaverageremainingcontractualterm": "P3Y1M20D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsexercisablenumber": 1900310,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionoutstandingweightedaverageexerciseprice": 5.016,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionsexercisableweightedaverageremainingcontractualterm": "P3Y1M20D",
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 5.7,
    "classofwarrantorrightoutstanding": 290000,
    "preferredstockconversionbasis": "Eachshare of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 2.0833 shares of common stock (subjectto customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversionrate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000",
    "conversionofstocksharesconverted1": 2.0833,
    "proceedsfromissuanceofconvertiblepreferredstock": 21875000,
    "shareprice": 0.5,
    "relatedpartycosts": 100000,
    "officerscompensation": 250000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 250000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingrightspercentage": 0.5,
    "sharebasedcompensation": 266020,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0303,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.2803,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P3Y6M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 2603125,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 2.918,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiod": 1650000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 1.337,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexpirationsinperiod": 421875,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsinreversestocksplitweightedaverageexerciseprice": 1.916,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P3Y14D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 2819792,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 3.283,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P2Y5M26D",
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeupperrangelimit": 0.5025,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofoutstandingoptions": 100000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptions": 100000,
    "commonstockcapitalsharesreservedforfutureissuance": 1530208,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestexercisableweightedaverageremainingcontractualterm1": "P15M",
    "deferredcompensationarrangementwithindividualcompensationexpense": 882000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 750,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 0.51,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestednumberofshares": 1075000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 574000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 2137000,
    "deferredtaxassetsoperatinglosscarryforwards": 8135000,
    "deferredtaxassetsgross": 10846000,
    "deferredtaxassetsvaluationallowance": 10846000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": -0.06,
    "effectiveincometaxratereconciliationsharebasedcompensationexcesstaxbenefitpercent": 0.017,
    "effectiveincometaxratereconciliationadjustmenttodeferredtaxasset": -0.015,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": 0.268,
    "deferredtaxassetsoperatinglosscarryforwardsdomestic": 27803000,
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 28040000,
    "operatinglosscarryforwardsexpirationdate1": "expirethrough 2038",
    "operatinglosscarryforwardslimitationsonuse": "The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. UnutilizedPNOLC amounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurredin post-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040",
    "priornetoperatinglossconversion": 928313,
    "contractualobligation": 7892000,
    "advanceamountrelatedtomilestonepayment": 26397,
    "othercommitmentsdescription": "The Company’s aggregate commitment pursuant tothis agreement, less amounts previously paid to date, totaled approximately $590,000 as of December 31, 2022, which is expected to beincurred through December 31, 2025",
    "othercommitment": 590000,
    "amountrelatedtomilestonepayment": 415823,
    "operatingcostsandexpenses": 25000,
    "paymentsforroyalties": 50000,
    "consultingandadvisorycashfee": 16000,
    "reimbursementexpense": 120000
  },
  {
    "date": "2021-12-30",
    "symbol": "LIXTW",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentperiodenddate": "2021-12-31",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2021,
    "currentfiscalyearenddate": "--12-31",
    "entityfilenumber": "000-51476",
    "entityregistrantname": "LIXTE BIOTECHNOLOGY HOLDINGS, INC.",
    "entitycentralindexkey": 1335105,
    "entitytaxidentificationnumber": "20-2903526",
    "entityincorporationstatecountrycode": "DE",
    "entityaddressaddressline1": "680     East Colorado Boulevard",
    "entityaddressaddressline2": "Suite 180",
    "entityaddresscityortown": "Pasadena",
    "entityaddressstateorprovince": "CA",
    "entityaddresspostalzipcode": 91101,
    "cityareacode": 631,
    "localphonenumber": "830-7092",
    "security12btitle": "Common     Stock, par value $0.0001 per share",
    "tradingsymbol": "LIXT",
    "securityexchangename": "NASDAQ",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "icfrauditorattestationflag": "false",
    "auditorfirmid": 572,
    "auditorname": "Weinberg & Company, P.A",
    "auditorlocation": "Los Angeles, California",
    "cashandcashequivalentsatcarryingvalue": 4823745,
    "advancesonresearchanddevelopmentcontractservices": 150241,
    "prepaidinsurance": 109029,
    "prepaidexpenseandotherassetscurrent": 10249,
    "assetscurrent": 5093264,
    "assets": 5093264,
    "accountspayableandaccruedliabilitiescurrent": 225965,
    "researchanddevelopmentcontractliabilitiescurrent": 76961,
    "liabilitiescurrent": 302926,
    "preferredstockvalue": 3500000,
    "commonstockvalue": 1374,
    "additionalpaidincapital": 38371128,
    "retainedearningsaccumulateddeficit": -37082164,
    "stockholdersequity": 4790338,
    "liabilitiesandstockholdersequity": 5093264,
    "accountspayablerelatedpartiescurrent": 32500,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 10000000,
    "preferredstocksharesissued": 350000,
    "preferredstocksharesoutstanding": 350000,
    "convertiblepreferredstocksharesissueduponconversion": 729167,
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": 100000000,
    "commonstocksharesissued": 13746593,
    "commonstocksharesoutstanding": 13746593,
    "generalandadministrativeexpense": 2931280,
    "legalfees": 729171,
    "othercostandexpenseoperating": 1323218,
    "researchanddevelopmentexpense": 1736776,
    "operatingexpenses": 6720445,
    "operatingincomeloss": -6720445,
    "investmentincomenonoperating": 626,
    "interestexpense": 7414,
    "foreigncurrencytransactiongainlossbeforetax": -1163,
    "netincomeloss": -6728396,
    "earningspersharebasicanddiluted": -0.5,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 13473839,
    "allocatedsharebasedcompensationexpense": 2201280,
    "sharesoutstanding": 350000,
    "stockissuedduringperiodvaluenewissues": 113,
    "stockissuedduringperiodsharesnewissues": 1133102,
    "stockissuedduringperiodvalueother": 1,
    "stockissuedduringperiodsharesother": 3000,
    "stockissuedduringperiodvaluestockoptionsexercised": 20,
    "stockissuedduringperiodsharesstockoptionsexercised": 208334,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 2598922,
    "generalandadministrativestockbasedcompensationexpenses": 2201280,
    "researchanddevelopmentcosts": 397642,
    "increasedecreaseinadvancesonresearchanddevelopmentcontractservices": 73343,
    "increasedecreaseinprepaidinsurance": 41718,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -4751,
    "increasedecreaseinaccountspayableandaccruedliabilities": 35673,
    "increasedecreaseinresearchanddevelopmentcontractliabilities": 61196,
    "netcashprovidedbyusedinoperatingactivities": -4142915,
    "proceedsfromissuanceofcommonstock": 3689761,
    "proceedsfromissuanceofwarrants": 17100,
    "proceedsfromstockplans": 201000,
    "paymentoffinancingandstockissuancecosts": 10467,
    "netcashprovidedbyusedinfinancingactivities": 3897394,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -245521,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 4823745,
    "interestpaidnet": 7414,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 729167,
    "cashfdicinsuredamount": 250000,
    "cashsipcinsuredamount": 500000,
    "patentandlicensingcosts": 729171,
    "concentrationriskpercentage1": 0.1,
    "deferredsetupandorganizationcostsamortizationperiod": "P12M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsoutstandingnumber": 3110310,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionoutstandingweightedaveragenumberofshare": 5.772,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsgranted": 113310,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptiongrantsinperiodweightedaverageexerciseprice": 3.7,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsexercised": 3000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionexercisedinperiodweightedaverageexerciseprice": 5.7,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionsoutstandingweightedaverageremainingcontractualterm": "P2Y5M23D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsexercisablenumber": 3110310,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionoutstandingweightedaverageexerciseprice": 5.772,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionsexercisableweightedaverageremainingcontractualterm": "P2Y5M23D",
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 5.7,
    "classofwarrantorrightoutstanding": 113310,
    "preferredstockconversionbasis": "Eachshare of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 2.0833 shares of common stock (subjectto customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversionrate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000.",
    "conversionofstocksharesconverted1": 2.0833,
    "proceedsfromissuanceofconvertiblepreferredstock": 21875000,
    "shareprice": 1.19,
    "relatedpartycosts": 822834,
    "officerscompensation": 250000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrateminimum": 0.0089,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestratemaximum": 0.0113,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrateminimum": 1.877,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityratemaximum": 1.988,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P3Y6M",
    "sharebasedcompensation": 100213,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 2666667,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 3.738,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiod": 1400000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 2.906,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 0.965,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsreversestocksplit": 1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P3Y5M1D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 2004167,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 3.77,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P3Y1M17D",
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeupperrangelimit": 0.9,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofoutstandingoptions": 33333,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptions": 33333,
    "sharesissued": 1400000,
    "commonstockcapitalsharesreservedforfutureissuance": 933333,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestexercisableweightedaverageremainingcontractualterm1": "P18Y",
    "deferredcompensationarrangementwithindividualcompensationexpense": 2097000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 10000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 1.19,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestednumberofshares": 662500,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 451000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1821000,
    "deferredtaxassetsoperatinglosscarryforwards": 6723000,
    "deferredtaxassetsgross": 8995000,
    "deferredtaxassetsvaluationallowance": 8995000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": -0.06,
    "effectiveincometaxratereconciliationsharebasedcompensationexcesstaxbenefitpercent": 0.006,
    "effectiveincometaxratereconciliationadjustmenttodeferredtaxasset": -0.004,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": 0.268,
    "deferredtaxassetsoperatinglosscarryforwardsdomestic": 23173000,
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 23287000,
    "operatinglosscarryforwardsexpirationdate1": "expire through 2041",
    "operatinglosscarryforwardslimitationsonuse": "The Company may utilize up to 1/10 of the PNOLC subtraction pool, or $928,313, each year. Unutilized PNOLCamounts carry forward to succeeding years until they expire in 2035. In addition, the full New York net operating losses incurred inpost-2015 tax years may be utilized in future tax years. Post-2015 New York net operating losses expire through 2040",
    "priornetoperatinglossconversion": 928313,
    "contractualobligation": 8646000,
    "advanceamountrelatedtomilestonepayment": 18443,
    "othercommitmentsdescription": "The Company’s aggregate commitment pursuant tothis agreement, less amounts previously paid to date, totaled approximately $601,000 as of December 31, 2021, which is expected to beincurred through December 31, 2025",
    "othercommitment": 601000,
    "amountrelatedtomilestonepayment": 67582,
    "operatingcostsandexpenses": 24999,
    "paymentsforroyalties": 50000,
    "consultingandadvisorycashfee": 16000,
    "reimbursementexpense": 120000
  },
  {
    "date": "2020-12-30",
    "symbol": "LIXTW",
    "period": "FY",
    "entityregistrantname": "LIXTE BIOTECHNOLOGY HOLDINGS, INC.",
    "entitycentralindexkey": 1335105,
    "documenttype": "10-K",
    "documentperiodenddate": "2020-12-31",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "icfrauditorattestationflag": "false",
    "entityshellcompany": "false",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2020,
    "cashandcashequivalentsatcarryingvalue": 5069266,
    "contractwithcustomerassetnetcurrent": 76898,
    "prepaidinsurance": 67311,
    "prepaidexpenseandotherassetscurrent": 15000,
    "assetscurrent": 5228475,
    "assets": 5228475,
    "accountspayableandaccruedliabilitiescurrent": 190292,
    "accruedofferingcostscurrent": 10467,
    "contractwithcustomerliabilitycurrent": 15765,
    "liabilitiescurrent": 216524,
    "preferredstockvalue": 3500000,
    "commonstockvalue": 1240,
    "additionalpaidincapital": 31864479,
    "retainedearningsaccumulateddeficit": -30353768,
    "stockholdersequity": -30353768,
    "liabilitiesandstockholdersequity": 5228475,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 9650000,
    "preferredstocksharesissued": 350000,
    "preferredstocksharesoutstanding": 350000,
    "preferredstockstatedvalue": 10,
    "convertiblepreferredstocksharesissueduponconversion": 729167,
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": 100000000,
    "commonstocksharesissued": 12402157,
    "commonstocksharessubscribedbutunissued": 12402157,
    "commonstocksharesoutstanding": 12402157,
    "generalandadministrativeexpense": 2042764,
    "researchanddevelopmentexpense": 700000,
    "operatingexpenses": 3266440,
    "operatingincomeloss": -3266440,
    "investmentincomenonoperating": 5232,
    "interestexpense": 3674,
    "netincomeloss": -3264882,
    "earningspersharebasicanddiluted": -0.29,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 11277126,
    "relatedpartytransactionsellinggeneralandadministrativeexpensesfromtransactionswithrelatedparty": 765085,
    "sharesoutstanding": 12402157,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 1151349,
    "stockissuedduringperiodvaluenewissues": 4591229,
    "stockissuedduringperiodsharesnewissues": 1200000,
    "stockissuedduringperiodvalueissuedforservices": 99997,
    "stockissuedduringperiodsharesissuedforservices": 27420,
    "extensionofstockoptions": 670715,
    "generalandadministrativestockbasedcompensationexpenses": 580634,
    "researchanddevelopmentstockbasedcompensationexpenses": 670715,
    "increasedecreaseincontractwithcustomerasset": 76898,
    "increasedecreaseinaccruedinterestreceivablenet": -14367,
    "increasedecreaseinprepaidinsurance": 32803,
    "increasedecreaseinprepaidexpensesother": -9294,
    "increasedecreaseinaccountspayableandaccruedliabilities": 46743,
    "increasedecreaseincontractwithcustomerliability": -78584,
    "netcashprovidedbyusedinoperatingactivities": 2131414,
    "proceedsfromissuanceofcommonstock": 4601816,
    "netcashprovidedbyusedinfinancingactivities": 4601816,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 2470402,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 5069266,
    "interestpaidnet": 3674,
    "liabilitiesassumed1": 10467,
    "cashfdicinsuredamount": 250000,
    "cashsipcinsuredamount": 500000,
    "insurancepremiumobligation": 175658,
    "interestrateofinsurancepremiumpayable": 0.0527,
    "patentandlicensingcosts": 553173,
    "concentrationriskpercentage1": 0.656,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 1475000,
    "conversionofstocksharesconverted1": 729167,
    "proceedsfromissuanceofconvertiblepreferredstock": 21875000,
    "preferredstockredemptionpricepershare": 50,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 5.7,
    "shareprice": 3.65,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsoutstandingnumber": 3000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsgranted": 1500000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsexercisablenumber": 2880000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionoutstandingweightedaveragenumberofshare": 5.85,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptiongrantsinperiodweightedaverageexerciseprice": 5.7,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionoutstandingweightedaverageexerciseprice": 5.85,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionsoutstandingweightedaverageremainingcontractualterm": "P3Y5M1D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionsexercisableweightedaverageremainingcontractualterm": "P3Y5M1D",
    "professionalfees": 38000,
    "allocatedsharebasedcompensationexpense": 480634,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 208333,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 1475000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestednumberofshares": 27420,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedinperiodfairvalue1": 100000,
    "sharebasedcompensation": 138926,
    "deferredcompensationarrangementwithindividualcompensationexpense": 894000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 747750,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 3.17,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestednumberofshares": 150000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrateminimum": 0.0023,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestratemaximum": 0.0031,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 2.0767,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P5Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiod": 200000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexpirationsinperiod": 33333,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 1325000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 4.136,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 7.14,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexpirationsinperiodweightedaverageexerciseprice": 3,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 3.796,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P3Y1M2D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P2Y11M1D",
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeupperrangelimit": 12,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofoutstandingoptions": 1475000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptions": 1325000,
    "deferredtaxassetsoperatinglosscarryforwardsdomestic": 19188000,
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 20087000,
    "operatinglosscarryforwardsexpirationdate1": "expire through 2040",
    "priornetoperatinglossconversion": 928313,
    "deferredtaxassetspreliminarycosts": 5000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 390000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1107000,
    "deferredtaxassetsoperatinglosscarryforwards": 5477000,
    "deferredtaxassetsgross": 6979000,
    "deferredtaxassetsvaluationallowance": 6979000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": -0.06,
    "effectiveincometaxratereconciliationsharebasedcompensationexcesstaxbenefitpercent": 0.005,
    "effectiveincometaxratereconciliationadjustmenttodeferredtaxasset": -0.008,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": 0.273,
    "losscontingencydamagespaidvalue": 41142,
    "advanceamountrelatedtomilestonepayment": 43411,
    "othercommitment": 300000,
    "othercommitmentsdescription": "The Company's aggregate commitments pursuant to the aforementioned clinical trial agreements, less amounts previously paid to date under these agreements, totaled approximately $5,230,000 as of December 31, 2020, consisting of approximately $4,614,000 relating to the GEIS clinical trial and approximately $616,000 relating to the Moffit clinical trial, which are expected to be incurred over the next five years through December 31, 2025.",
    "amountchargetooperations": 131650,
    "royaltiesdescription": "The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement.",
    "paymentsforroyalties": 100000,
    "salarieswagesandofficerscompensation": 45000,
    "otherlaborrelatedexpenses": 46451,
    "paymentformanagementfee": 79995,
    "consultingandadvisorycashfee": 16000,
    "reimbursementexpense": 11650
  },
  {
    "date": "2019-12-30",
    "symbol": "LIXTW",
    "period": "FY",
    "entityregistrantname": "LIXTE BIOTECHNOLOGY HOLDINGS, INC.",
    "entitycentralindexkey": 1335105,
    "documenttype": "10-K",
    "documentperiodenddate": "2019-12-31",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2019,
    "cashandcashequivalentsatcarryingvalue": 2598864,
    "interestreceivablecurrent": 14367,
    "prepaidexpenseandotherassetscurrent": 58802,
    "assetscurrent": 2672033,
    "assets": 2672033,
    "accountspayableandaccruedliabilitiescurrent": 143549,
    "researchanddevelopmentcontractliabilitiescurrent": 94349,
    "liabilitiescurrent": 237898,
    "preferredstockvalue": 3500000,
    "commonstockvalue": 6704,
    "additionalpaidincapital": 26016317,
    "retainedearningsaccumulateddeficit": -27088886,
    "stockholdersequity": -27088886,
    "liabilitiesandstockholdersequity": 2672033,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 9650000,
    "preferredstocksharesissued": 350000,
    "preferredstocksharesoutstanding": 350000,
    "preferredstockstatedvalue": 10,
    "preferredstockredemptionpricepershare": 50,
    "preferredstockredemptionamount": 17500000,
    "convertiblepreferredstocksharesissueduponconversion": 4375000,
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": 100000000,
    "commonstocksharesissued": 67045814,
    "commonstocksharesoutstanding": 67045814,
    "generalandadministrativeexpense": 1669160,
    "researchanddevelopmentexpense": 100000,
    "operatingexpenses": 2490066,
    "operatingincomeloss": -2490066,
    "investmentincomenonoperating": 49723,
    "netincomeloss": -2440343,
    "earningspersharebasicanddiluted": -0.04,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 67045814,
    "relatedpartytransactionsellinggeneralandadministrativeexpensesfromtransactionswithrelatedparty": 362631,
    "sharesoutstanding": 67045814,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 748655,
    "generalandadministrativestockbasedcompensationexpenses": 314631,
    "researchanddevelopmentstockbasedcompensationexpenses": 434024,
    "increasedecreaseinaccruedinterestreceivablenet": 14367,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -4924,
    "increasedecreaseinaccountspayableandaccruedliabilities": -51662,
    "increasedecreaseinresearchanddevelopmentcontractliabilities": 78645,
    "netcashprovidedbyusedinoperatingactivities": -1674148,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -1674148,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 2598864,
    "patentandlicensingcosts": 742918,
    "concentrationriskpercentage1": 0.107,
    "deferredsetupandorganizationcostsamortizationperiod": "P180M",
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 7850000,
    "conversionofstocksharesconverted1": 12.5,
    "proceedsfromissuanceofconvertiblepreferredstock": 21875000,
    "preferredstockconversionbasis": "Each share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 12.5 shares of common stock (subject to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000. ",
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionsexercisableweightedaverageexerciseprice": 0.68,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsoutstandingnumber": 9000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionoutstandingweightedaveragenumberofshare": 1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionsoutstandingweightedaverageremainingcontractualterm": "P2Y11M1D",
    "salarieswagesandofficerscompensation": 60000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 1250000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 0.608,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P3Y1M20D",
    "professionalfees": 48000,
    "allocatedsharebasedcompensationexpense": 314631,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 1250000,
    "stockoptionplanexpense": 31046,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 1664950,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 0.68,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrateminimum": 0.0147,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestratemaximum": 0.0185,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrateminimum": 1.3301,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityratemaximum": 1.7187,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P5Y",
    "sharebasedcompensation": 434024,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiod": 800000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexpirationsinperiod": 700000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 7850000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 0.608,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 1.038,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexpirationsinperiodweightedaverageexerciseprice": 0.321,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P3Y1M20D",
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeupperrangelimit": 2,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofoutstandingoptions": 500000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptions": 500000,
    "deferredtaxassetsoperatinglosscarryforwardsdomestic": 17088000,
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 17987000,
    "operatinglosscarryforwardsexpirationdate1": "expire through 2039",
    "priornetoperatinglossconversion": 928367,
    "deferredtaxassetspreliminarycosts": 10000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 359000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 799000,
    "deferredtaxassetsoperatinglosscarryforwards": 4879000,
    "deferredtaxassetsgross": 6047000,
    "deferredtaxassetsvaluationallowance": 6047000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": -0.06,
    "effectiveincometaxratereconciliationexpirationsrelatedtostockbasedcompensation": 0.012,
    "effectiveincometaxratereconciliationadjustmenttodeferredtaxasset": -0.003,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": 0.261,
    "othercommitment": 5000000,
    "othercommitmentsdescription": "The Company's aggregate commitments pursuant to these clinical trial agreements, less amounts previously incurred to date under these agreements, totaled approximately $5,000,000 as of December 31, 2019, which are expected to be incurred over the next five years through 2024.",
    "amortizingretainerpayment": 9174,
    "prepaidexpensecurrentandnoncurrent": 2294,
    "amountchargetooperations": 80669,
    "royaltiesdescription": "The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement.",
    "paymentsforroyalties": 100000,
    "consultingandadvisorycashfee": 16000
  }
]